Most researchers looking for CJC-1295 in As rapidly learn that local retail options are virtually absent. The key implication for As researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the evaluation methodology is universal across all locations. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. The sections below cover what As researchers need to know about purchasing, testing, and working with CJC-1295 for scientific research use.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For As researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
The most effective path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums maintain informal vendor reputation databases that are more reliable than search results. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are within acceptable research limits. For As researchers evaluating unfamiliar vendors: a modest first purchase to test the product before placing larger orders is what experienced peptide researchers consistently do. Store lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order CJC-1295 — ships to As
COA-verified · International tracking · Research grade
All use of CJC-1295 in As or anywhere constitutes research use — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Temperature excursions — even brief warming above recommended storage temperature — can compromise product integrity without any obvious sign; always use only material shipped with appropriate cold protection. The main safety concern arising from sourcing in CJC-1295 research is endotoxin contamination from poor sourcing — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. PubMed represent the most comprehensive research databases for CJC-1295 research; prioritise peer-reviewed studies with characterised source material over unreviewed preprints or forum reports.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
